VEGFR

2 drugs

Predictive biomarker for patient selection in 3 indications

Approved Drugs

Indications

Companies

VEGFR is a precision-medicine biomarker linked to 2 FDA-approved targeted drugs from 2 companies, spanning 3 indications including Medullary Thyroid Cancer, Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia, Chronic Myeloid Leukemia. Explore the targeted therapies, indications, testing methods, and companies developing VEGFR drugs below.

Search VEGFR Clinical Trials

Search recruiting trials on ClinicalTrials.gov

Drugs Targeting VEGFR

Drug	Company	Therapeutic Area
CAPRELSA	Sanofi	Oncology
ICLUSIG	Takeda	Oncology

VEGFR Indications

Medullary Thyroid Cancer Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia Chronic Myeloid Leukemia

Companies with VEGFR Drugs

Sanofi Takeda